Portal de Periódicos da CAPES

Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.

2006; National Institutes of Health; Volume: 91; Issue: 6 Linguagem: Inglês

Gamal Sidra, Cathy Williams, Nigel H. Russell, Sonya Zaman, Bethan Myers, Jenny Byrne,

Hematopoietic Stem Cell Transplantation

We evaluated the combination of thalidomide, pulsed dexamethasone and weekly cyclophosphamide (CTD) for the treatment of patients with newly diagnosed, relapsed or VAD-refractory multiple myeloma. We found that this combination was highly effective in inducing responses in all treatment groups with an overall response rate of 83.8%. CTD was well tolerated and did not impair stem cell mobilization.